PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24269936-6 2014 Interestingly, only 2 mg/kg dose of METH-induced locomotor sensitization which was accompanied by the activation of ERK1/2 in the NAc and CPu in mice. Methamphetamine 36-40 mitogen-activated protein kinase 3 Mus musculus 116-122 30433806-8 2019 The phosphorylated extracellular regulated protein kinase 1/2 (p-ERK1/2), an important regulator of HCN channels, was also obviously reduced in hippocampus and prefrontal cortex of mice with METH re-exposure. Methamphetamine 191-195 mitogen-activated protein kinase 3 Mus musculus 65-71 30433806-10 2019 Overall, our data firstly showed the aberrant protein expression of HCN1 channels in METH re-exposed mice with enhanced working memory, which was probably related to the down-regulation of p-ERK1/2 protein expression. Methamphetamine 85-89 mitogen-activated protein kinase 3 Mus musculus 191-197 29414647-10 2018 While MAPK activation was not influenced by METH alone, the LPS-induced phosphorylation of p38, JNK and ERK1/2 were all reduced by METH. Methamphetamine 131-135 mitogen-activated protein kinase 3 Mus musculus 104-110 29414647-13 2018 Moreover, the inhibition of the phosphorylation of ERK1/2 by METH was also reversed. Methamphetamine 61-65 mitogen-activated protein kinase 3 Mus musculus 51-57 31078920-14 2019 Moreover, phosphorylation of ERK1/2 and CREB was increased after METH and LPS exposure but decreased by SCH-23390. Methamphetamine 65-69 mitogen-activated protein kinase 3 Mus musculus 29-35 27544406-0 2016 Ifenprodil attenuates the acquisition and expression of methamphetamine-induced behavioral sensitization and activation of Ras-ERK1/2 cascade in the caudate putamen. Methamphetamine 56-71 mitogen-activated protein kinase 3 Mus musculus 127-133 27544406-7 2016 Western blot analysis revealed that pre-injection of low-dose ifenprodil in the acquisition markedly attenuated METH-induced ascent of Ras, pERK1/2/ERK1/2, and DeltaFosB protein levels in the CPu. Methamphetamine 112-116 mitogen-activated protein kinase 3 Mus musculus 141-147 27544406-9 2016 Moreover, chronic METH administration increased pERK1/2/ERK1/2 level in the NAc. Methamphetamine 18-22 mitogen-activated protein kinase 3 Mus musculus 49-55 24269936-7 2014 Although l-THP (5 and 10 mg/kg) per se did not induce obvious changes in locomotor activities in mice, its co-administration with METH could significantly attenuate acute METH-induced hyper-locomotor activity, the development and expression of METH-induced locomotor sensitization, and the accompanying ERK1/2 activation in the NAc and CPu. Methamphetamine 130-134 mitogen-activated protein kinase 3 Mus musculus 303-309 22369785-2 2012 In order to investigate this sex difference we studied the involvement of Akt and extracellular signal-regulated kinase (ERK1/2) in methamphetamine toxicity as a function of time post-treatment (30 min, 1 and 3 days). Methamphetamine 132-147 mitogen-activated protein kinase 3 Mus musculus 121-127 22369785-8 2012 An increase in the phosphorylation of striatal Akt (after 1 day), glycogen synthase kinase 3beta (at 1 and 3 days) and ERK1/2 (30 min post-methamphetamine) was only observed in females. Methamphetamine 139-154 mitogen-activated protein kinase 3 Mus musculus 119-125 20219155-10 2010 These results suggest that the ameliorating effect of galantamine on Meth-induced memory impairment is associated with indirect activation of dopamine D1 receptor-ERK1/2 following augmentation with dopaminergic neurotransmission in the PFC through the allosteric activation of nAChRs. Methamphetamine 69-73 mitogen-activated protein kinase 3 Mus musculus 163-169 21236583-2 2011 The present study evaluated the involvement of phosphatidylinositol-3 kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK1/2) pathways in this sex-dependent methamphetamine toxicity. Methamphetamine 170-185 mitogen-activated protein kinase 3 Mus musculus 131-137 22530033-12 2012 Interestingly, a single administration of METH (3 mg/kg) significantly increased the phosphorylation status of ERK1/2 in the striatum of WT, but not Srr-KO mice. Methamphetamine 42-46 mitogen-activated protein kinase 3 Mus musculus 111-117 22530033-13 2012 CONCLUSIONS/SIGNIFICANCE: These findings suggest first, that SRR plays a role in the development of behavioral sensitization in mice after repeated administration of METH, and second that phosphorylation of ERK1/2 by METH may contribute to the development of this sensitization as seen in WT but not Srr-KO mice. Methamphetamine 166-170 mitogen-activated protein kinase 3 Mus musculus 207-213 22530033-13 2012 CONCLUSIONS/SIGNIFICANCE: These findings suggest first, that SRR plays a role in the development of behavioral sensitization in mice after repeated administration of METH, and second that phosphorylation of ERK1/2 by METH may contribute to the development of this sensitization as seen in WT but not Srr-KO mice. Methamphetamine 217-221 mitogen-activated protein kinase 3 Mus musculus 207-213 20486560-5 2010 Repeated methamphetamine treatment in mice impairs long-term recognition memory after withdrawal, which is associated with the dysfunction in dopamine D1 receptor-extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in the prefrontal cortex. Methamphetamine 9-24 mitogen-activated protein kinase 3 Mus musculus 206-212 34102646-3 2021 Our previous study demonstrated that the activity of protein phosphatase 2A (PP2A) and the level of phosphorylated extracellular signal-related kinase 1/2 (p-ERK 1/2) are increased in the caudate putamen (CPu) of METH-sensitive mice. Methamphetamine 213-217 mitogen-activated protein kinase 3 Mus musculus 158-165 17909751-7 2008 The improvement in memory caused by minocycline was associated with an amelioration of the novelty-induced activation of extracellular signal-regulated kinase 1/2 in the prefrontal cortex of METH-treated mice. Methamphetamine 191-195 mitogen-activated protein kinase 3 Mus musculus 121-162 17090702-0 2007 A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. Methamphetamine 105-120 mitogen-activated protein kinase 3 Mus musculus 184-225 17090702-3 2007 ZSET1446 (1 microg/kg) recovered the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the prefrontal cortex (PFC) of METH-treated mice. Methamphetamine 166-170 mitogen-activated protein kinase 3 Mus musculus 81-122 17090702-3 2007 ZSET1446 (1 microg/kg) recovered the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the prefrontal cortex (PFC) of METH-treated mice. Methamphetamine 166-170 mitogen-activated protein kinase 3 Mus musculus 124-130 17090702-7 2007 These results suggest that the ameliorative effect of ZSET1446 on METH-induced memory impairment is associated with indirect activation of ERK1/2 following stimulation with dopamine D1 and NMDA receptors of the PFC. Methamphetamine 66-70 mitogen-activated protein kinase 3 Mus musculus 139-145 16139811-0 2006 Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Methamphetamine 9-24 mitogen-activated protein kinase 3 Mus musculus 99-105 16139811-9 2006 Hyperphosphorylation of ERK1/2 was found in the prefrontal cortex of mice exposed to the novel objects, but was abolished in mice treated with METH. Methamphetamine 143-147 mitogen-activated protein kinase 3 Mus musculus 24-30 16139811-11 2006 CONCLUSIONS: These results suggest that repeated METH treatment induces cognitive impairment, which is associated with the dysfunction of the ERK1/2 pathway in the prefrontal cortex. Methamphetamine 49-53 mitogen-activated protein kinase 3 Mus musculus 142-148 34102646-9 2021 Furthermore, Western blot analysis revealed that pretreatment with 2 mg/kg LB100 remarkably reversed METH-induced reduction of p-Raf1, as well as upregulation of p-ERK 1/2 in the CPu. Methamphetamine 101-105 mitogen-activated protein kinase 3 Mus musculus 164-171 34102646-10 2021 Taken together, these results indicate that PP2A plays an important role in METH-induced behavioral sensitization and phosphorylates ERK 1/2 by dephosphorylating p-Raf1 in the CPu to further regulate METH-induced behavioral sensitization. Methamphetamine 200-204 mitogen-activated protein kinase 3 Mus musculus 133-140 32777257-14 2020 CONCLUSION: The findings indicated that the development of behavioural sensitization to METH may be mediated by Fas and GIT1 through the MEK1-Erk1/2-CREB pathway. Methamphetamine 88-92 mitogen-activated protein kinase 3 Mus musculus 142-148 32777257-10 2020 The detection of gene expression by RT-PCR indicated that METH-sensitized mice exhibited decreased levels of Fas, MEK1 and CREB and increased levels of Erk1/2 in the PFC. Methamphetamine 58-62 mitogen-activated protein kinase 3 Mus musculus 152-158 32777257-11 2020 Western blot analysis revealed decreased Fas, GIT1, MEK1 and phosphorylated CREB levels and increased phosphorylated Erk1/2 levels in METH-sensitized mice. Methamphetamine 134-138 mitogen-activated protein kinase 3 Mus musculus 117-123